Let's not put all our eggs in one basket

New England Journal of Medicine

Volumn 373, Issue 8, 2015, Pages 691-693

  Hunter, David J ^a   D'Agostino, Ralph B ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; INDOLE DERIVATIVE; SULFONAMIDE;

ADVERSE DRUG REACTION; BRAF GENE; CANCER CLASSIFICATION; CHRONIC MYELOID LEUKEMIA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EGFR GENE; HUMAN; METASTATIC MELANOMA; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMATIC MUTATION; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENETICS; HISTIOCYTOSIS; MALE; MUTATION; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HISTIOCYTOSIS; HUMANS; INDOLES; MALE; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84939818116     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1508144     Document Type: Article

References (5)

1. Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med 2013; 369: 2369-71.
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
4. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
5. Menis J, Hasan B, Besse B. New clinical research strategies in thoracic oncology: Clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur Respir Rev 2014; 23: 367-78.